Alk-abello A/s Class B · OMXCOP:ALK_B
Alk-abello A/s Class B — Alk-Abello As B Shs New — Q4 2025 Earnings Presentation
12 slides from Alk-abello A/s Class B's earnings presentation, Feb 20, 2026
Slide 1: FY 2025 presentation
FY 2025 presentation Webcast 20 February 2026
Slide 2: Agenda and presenters
2 Webcast 20 February 2026 Agenda and presenters • Q4 highlights • Full-year highlights • Sales regions • Product lines • FY financials President & CEO EVP, Group CFO VP, Head of IR • Strategic advancements Peter Halling Claus Steensen Sølje Per Plotnikof • 2026 outlook • Q&A session This presentati
Slide 3: Q4 highlights
3 Webcast 20 February 2026 Q4 highlights Solid performance in Q4 leads to full-year results at the top end of the latest outlook Strategy execution Revenue DKKm • Paediatric launches of ACARIZAX® and ITULAZAX® 2,000 +17% 20% progressed well in key markets 15% 1,500 • Ongoing roll-out of neffy® in e.
Slide 4: Full-year highlights
4 Webcast 20 February 2026 Full-year highlights A landmark year. ‘25in25’ milestone achieved • Revenue growth of 15% driven by double-digit growth in all regions • Solid expansion of patient base: 3.1m now treated with ALK products (+0.5m) • EBIT margin of 26% on higher sales and gross margin, modes
Slide 5: Double-digit growth in all sales regions
5 Webcast 20 February 2026 Double-digit growth in all sales regions Continued expansion of patient base in Europe and North America Europe North America International markets 71% 16% 13% Higher tablet volumes from strong Growth fueled by tablets, neffy® co- In-market double-digit growth in inflow of
Slide 6: Tablets and anaphylaxis as key growth drivers
6 Webcast 20 February 2026 Tablets and anaphylaxis as key growth drivers Well-above 10% growth in new patients starting tablet treatment in 2025 Anaphylaxis Tablets SCIT/SLIT-drops & other products 53% 34% 13% Expanding patient and prescriber bases Resumed shipments to China and Growth mainly driven
Slide 7: Strong margins and cash-flow
7 Webcast 20 February 2026 Strong margins and cash-flow Profitability driven up by higher sales, favourable mix, and efficiencies DKK million 2025 2024 Change Gross profit DKKm 5.000 70% Revenue 6,312 5,537 +15% 4.000 65% 3.000 Gross profit 4,234 3,552 2.000 60% 1.000 Gross margin 67% 64% 0 55% 2021
Slide 8: Progress with Allergy+ execution (1/2)
8 Webcast 20 February 2026 Progress with Allergy+ execution (1/2) 3.1 million patients treated in 2025, ~500k more than 2024 Respiratory allergy • Paediatric launches in 21 countries for house dust mite and in 12 for tree tablets • +4,000 paediatric tablet prescribers and high cross-tablet adoption
Slide 9: Progress with Allergy+ execution (2/2)
9 Webcast 20 February 2026 Progress with Allergy+ execution (2/2) R&D pipeline programmes on track Food allergy • Peanut tablet in phase 2 with FDA Fast Track. Topline results expected in Q2 • 2026 focus: Advance peanut tablet into program to phase 3 New disease areas • neffy ® advanced into phase 2
Slide 10: 2026 outlook
10 Webcast 20 February 2026 2026 outlook Robust revenue and earnings growth in line with long-term financial ambitions Revenue Key assumptions 11-15% DKKm Revenue Growth in l.c. • Volume-driven growth across regions and product groups 8.000 20% • Double-digit growth in tablet sales 15% 6.000 Growth
Slide 11: Q&A session
Q&A session
Slide 12: Upcoming events & Financial Calendar
12 Webcast 20 February 2026 Upcoming events & Financial Calendar Upcoming events: Financial Calendar: 23 February Copenhagen Roadshow 16 March Annual General Meeting 24 February London Roadshow 5 May Three-month interim report (Q1) 5 March Paris Roadshow 20 August Six-month interim report (Q2) 10-11
Alk-Abello As B Shs New — Q4 2025 Earnings Presentation on 6ix